NASDAQ: CGTXCognition Therapeutics Inc Stock
$0.43+0.03 (+7.5%)
Updated Oct 14, 2024
CGTX Price
$0.43
Fair Value Price
$0.99
Market Cap
$17.10M
52 Week Low
$0.34
52 Week High
$2.95
P/E
-0.45x
P/B
0.74x
P/S
N/A
PEG
N/A
Dividend Yield
N/A
Revenue
$0.00
Earnings
-$31.08M
Gross Margin
N/A
Operating Margin
N/A
Profit Margin
N/A
Debt to Equity
0.49
Operating Cash Flow
-$23M
Beta
1.14
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A
CGTX Overview
Cognition Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing small molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system and retina. Its lead candidate, CT1812, is an orally delivered, small molecule antagonist designed to penetrate the blood-brain barrier and bind selectively to the S2R ̣(sigma-2 receptor) complex. The company also intends to develop and advance candidates in the area of synucleinopathies. Cognition Therapeutics was incorporated in 2007 and is headquartered in Purchase, NY.
Zen Score
–
Industry Average (23)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how CGTX scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
CGTX ($0.43) is undervalued by 57% relative to our estimate of its Fair Value price of $0.99 based on Discounted Cash Flow (DCF) modelling, but does not have a significant margin of safety
Below Fair Value Valuation
CGTX ($0.43) is significantly undervalued by 57% relative to our estimate of its Fair Value price of $0.99 based on Discounted Cash Flow (DCF) modelling, which includes a healthy margin of safety
Significantly Below Fair Value Valuation
CGTX is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more CGTX due diligence checks available for Premium users.
Be the first to know about important CGTX news, forecast changes, insider trades & much more!
CGTX News
Valuation
CGTX fair value
Fair Value of CGTX stock based on Discounted Cash Flow (DCF)
Price
$0.43
Fair Value
$0.99
Undervalued by
56.59%
CGTX ($0.43) is undervalued by... subscribe to Premium to read more.
Below Fair Value Valuation
CGTX ($0.43) is significantly undervalued... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
CGTX is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
CGTX price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-0.45x
Industry
-124.07x
Market
27.44x
CGTX price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
0.74x
Industry
6.12x
CGTX is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
CGTX's financial health
Profit margin
Revenue
$0.0
Net Income
-$7.0M
Profit Margin
0%
CGTX's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
Assets to liabilities
Assets
$34.4M
Liabilities
$11.4M
Debt to equity
0.49
CGTX's short-term assets ($33.55M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
CGTX's short-term assets ($33.55M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
CGTX's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$6.0M
Investing
-$3.0k
Financing
-$138.0k
CGTX's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
CGTX vs Biotech Stocks
Cognition Therapeutics Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.